Skip to main content

Table 2 Baseline characteristics of individuals and clusters

From: Study of assessment of knowledge and understanding for coping with sick days among patients with diabetes in community pharmacy: a cluster randomized controlled trial (SAKURA trial)

 

Intervention group

Control group

Cluster level

  

No. of pharmacies

5

5

Cluster type

  

Pharmacies by the hospital*

  

Diabetes specialist

1

1

No diabetes specialist

1

1

Pharmacies by the clinic†

  

Small (50–99)

2

2

Large (> 100)

1

1

Individual level

  

No. of patients

92

178

Mean (SD) age (years)

67.1 (10.5)

66.1 (11.7)

Sex

Male/female/unknown

49/43/0

113/60/5

Diabetes medication (%)

  

Sulphonylurea

21/92 (22.8)

29/173 (16.8)

Glinide

5/92 (5.4)

22/173 (12.7)

α-GI

16/92 (17.4)

32/173 (18.5)

Biguanide

44/92 (47.8)

88/173 (50.9)

Thiazolidine

5/92 (5.4)

16/173 (9.2)

DPP-4

57/92 (62.0)

122/173 (70.5)

SGLT2

26/92 (28.3)

81/173 (46.8)

GLP-1

5/92 (5.4)

6/173 (3.5)

Insulin

10/92 (10.9)

11/173 (6.4)

  1. *Hospitals were categorized by the presence or absence of a diabetes specialist
  2. †Clinics were categorized by the number of diabetic patients visiting pharmacies next to the clinic a month. Small 50–99, large > 100
  3. SD standard deviation
  4. α-GI α-glucosidase inhibitor, DPP-4 dipeptidyl peptidase 4 inhibitor, SGLT2 sodium–glucose cotransporter 2 inhibitor, GLP-1 glucagon-like peptide 1 agonist
Back to article page

Journal of Pharmaceutical Policy and Practice

ISSN: 2052-3211

Contact us